Jean-Baptiste B.
- Country
- France
- Department
- Departement de Cardiologie
Research Overview
- Phase 3 Randomized Study Comparing Asundexian and Apixaban for Stroke Prevention in Atrial Fibrillation Patients at Risk
- Phase 3 Double-Blind, Placebo-Controlled Trial Evaluating Plozasiran Efficacy and Safety in Adults with Severe Hypertriglyceridemia
- A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation
Data & Insights
Has run more than one trial at 125 of 702 partner sites.
Specializations
Cardiovascular Disorders
Specializes in investigating therapeutic approaches for atrial fibrillation and its complications, with particular emphasis on stroke prevention strategies and management of cardioembolic events.
- Cardiac Rhythm Management
- Stroke Prevention
- Anticoagulation Therapy
Active involvement in evaluating novel anticoagulant treatments for cardiac conditions.
Metabolic Disorders
Focuses on the treatment of severe hypertriglyceridemia, investigating innovative therapeutic approaches for managing lipid disorders and their associated complications.
- Lipid Management
- Triglyceride Reduction
- Metabolic Disease Treatment
Expertise in evaluating new therapeutic agents for metabolic conditions.
Heart Failure Management
Conducts research in heart failure treatment optimization, particularly focusing on patients with recovered left ventricular ejection fraction and the role of beta-blocker therapy.
- Cardiac Function Recovery
- Medication Management
- Cardiovascular Outcomes
Specialized interest in treatment strategies for improved cardiac function.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.